Stansberry Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Stansberry Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-115,638	Closed	-$9.19M	–	61
2019 Q4	$9.19M	Sell	115,638 -3,734	-3%	-$221K	3.74%	7
2019 Q3	$5.79M	Buy	119,372 +4,810	+4%	+$251K	2.56%	15
2019 Q2	$6.03M	Sell	114,562 -6,032	-5%	-$347K	2.37%	14
2019 Q1	$6.38M	Buy	120,594 +43,695	+57%	+$2.15M	2.19%	14
2018 Q4	$3.16M	Sell	76,899 -7,680	-9%	-$288K	0.99%	20
2018 Q3	$3.21M	Sell	84,579 -34,196	-29%	-$1.51M	0.9%	34
2018 Q2	$5.37M	Buy	118,775 +67,363	+131%	+$3.07M	1.78%	19
2018 Q1	$2.48M	Buy	51,412 +111	+0.2%	+$6.19K	1.22%	31
2017 Q4	$2.02M	Buy	+51,301	New	+$1.92M	0.87%	36

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Stansberry Asset Management's GBT Position: Q1 2020 in Review

Stansberry Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2020, closing a stake of 115,638 shares — an estimated $9.19M sold.

Stansberry Asset Management first reported a position in GBT in Q4 2017 and held it in 9 quarters. The position peaked at $9.19M in Q4 2019. 220 funds tracked by Wall St. Rank hold GBT as of Q1 2020.

Stansberry Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Stansberry Asset Management sold 115,638 Global Blood Therapeutics, Inc. shares in Q1 2020, an estimated $9.19M.
Stansberry Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 9 quarters.
Stansberry Asset Management's Global Blood Therapeutics, Inc. position peaked at $9.19M in Q4 2019.
220 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2020.

Based on Stansberry Asset Management's 13F filing for Q1 2020, filed 15 May 2020.